A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Pan, Qiu Zhong ^a   Wang, Qi Jing ^a   Dan, Jia Qiang ^b   Pan, Ke ^a   Li, Yong Qiang ^a   Zhang, Yao Jun ^a   Zhao, Jing Jing ^a   Weng, De Sheng ^a   Tang, Yan ^a   Huang, Li Xi ^a   He, Jia ^a   Chen, Shi Ping ^a   Ke, Miao La ^a   Chen, Min Shan ^a   Wicha, Max S ^c   Chang, Alfred E ^c   Zeng, Yi Xin ^a   Li, Qiao ^c   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b CHENGDU FIFTH PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CYTOKINE INDUCED KILLER CELL; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84924942315     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09202     Document Type: Article

References (37)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin. 61, 69-90 (2011).
2. Maluccio, M. & Covey, A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62, 394-399 (2012).
3. El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132, 2557-2576 (2007).
4. Llovet, J. M. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 40, 225-235 (2005).
5. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet. 379, 1245-1255 (2012).
6. Pang, R. W. & Poon, R. T. Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. Curr Cancer Drug Targets. 12, 1081-1094 (2012).
7. Lu, P. H. & Negrin, R. S. A novel population of expanded human CD31 CD561 cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 153, 1687-1696 (1994).
8. Alvarnas, J. C., Linn, Y. C., Hope, E. G. & Negrin, R. S. Expansion of cytotoxic CD31 CD561 cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 7, 216-222 (2001).
9. Hui, K. M. CIK cells - current status, clinical perspectives and future prospects - the good news. Expert Opin Biol Ther. 12, 659-661 (2012).
10. Mesiano, G. et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 12, 673-684 (2012).
11. Thanendrarajan, S., Kim, Y. & Schmidt-Wolf, I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther. 12, 565-572 (2012).
12. Hui, D., Qiang, L., Jian, W., Ti, Z. & Da-Lu, K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 41, 36-41 (2009).
13. Laport, G. G. et al.Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 17, 1679-1687 (2011).
14. Li, J. J. et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 35, 189-195 (2012).
15. Pan, K. et al. Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer. Clin Cancer Res. 20, 3003-3011 (2014).
16. Shi, L. et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 61, 2251-2259 (2012).
17. Olioso, P. et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 27, 130-139 (2009).
18. Liu, L. et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 18, 1751-1759 (2012).
19. Pan, K. et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 20, 4305-4311 (2013).
20. Ma, Y. et al. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 1, 11 (2012).
21. Harrell, F. E., Jr., Lee, K. L. &Mark, D. B.Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 15, 361-387 (1996).
22. Altman, D. G. & Royston, P. What do we mean by validating a prognostic model? Stat Med. 19, 453-473 (2000).
23. Harrell, F. in Regression modeling strategies (ed. Harrell, F.) 1-568 (Springer-Verlag, 2001).
24. Freedman, A. N. et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 97, 715-723 (2005).
25. Li, J. et al. A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy. Br J Cancer. 110, 1110-1117 (2014).
26. Previs, R. A. et al. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Gynecol Oncol. 132, 531-536 (2014).
27. Eil, R. et al. Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: a SEER-Medicare analysis. Cancer. 120, 492-498 (2014).
28. Song, C. et al. Nomogram prediction of survival and recurrence in patients with extrahepatic bile duct cancer undergoing curative resection followed by adjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys. 87, 499-504 (2013).
29. Olivotto, I. A. et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 23, 2716-2725 (2005).
30. Stephenson, A. J. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 25, 2035-2041 (2007).
31. Wang, S. J. et al. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol. 26, 2112-2117 (2008).
32. Karakiewicz, P. I., Sun, M., Bellmunt, J., Sneller, V. & Escudier, B. Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria. Eur Urol. 60, 48-56 (2011).
33. Wang, Y. et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 31, 1188-1195 (2013).
34. Motzer, R. J. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 113, 1552-1558 (2008).
35. Vickers, A. J. Prediction models in cancer care. CA Cancer J Clin. 61, 315-326 (2011).
36. Sternberg, C. N. Are nomograms better than currently available stage groupings for bladder cancer? J Clin Oncol. 24, 3819-3820 (2006).
37. Touijer, K. & Scardino, P. T. Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer. 115, 3107-3111 (2009).